Alpine Global Management’s Aldeyra Therapeutics ALDX Stock Holding History

Alpine Global Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,025	Closed	-$64K	–	503
2022 Q3	$64K	Hold	12,025	–	–	0.02%	133
2022 Q2	$48K	Hold	12,025	–	–	0.01%	170
2022 Q1	$53	Sell	12,025 -10,582	-47%	-$42.2K	0.01%	309
2021 Q4	$90K	Buy	+22,607	New	+$172K	0.01%	676
2021 Q1	–	Sell	-27,873	Closed	-$191K	–	310
2020 Q4	$191K	Buy	+27,873	New	+$196K	0.04%	134

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alpine Global Management's ALDX Position: Q4 2022 in Review

Alpine Global Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2022, closing a stake of 12,025 shares — an estimated $64K sold.

Alpine Global Management first reported a position in ALDX in Q4 2020 and held it in 5 quarters. The position peaked at $191K in Q4 2020. 96 funds tracked by Wall St. Rank hold ALDX as of Q4 2022.

Alpine Global Management reported no remaining Aldeyra Therapeutics position as of Q4 2022 after selling out during the quarter.
Alpine Global Management sold 12,025 Aldeyra Therapeutics shares in Q4 2022, an estimated $64K.
Alpine Global Management first reported a position in Aldeyra Therapeutics in Q4 2020 and held it in 5 quarters.
Alpine Global Management's Aldeyra Therapeutics position peaked at $191K in Q4 2020.
96 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2022.

Based on Alpine Global Management's 13F filing for Q4 2022, filed 14 Feb 2023.